SAN FRANCISCO – A variety of new, repurposed, and reformulated compounds have made their way into clinical trials for systemic lupus erythematosus, as evidenced by an abstracts session devoted to...
SAN FRANCISCO – Valid diagnostic criteria for cryopyrin-associated periodic syndromes are sorely needed, and a new model of CAPS diagnostic criteria enables rapid diagnosis of this rare,...
SAN FRANCISCO – Adalimumab was the clear winner over infliximab and etanercept for anterior uveitis in a Scandinavian database study of 1,365 patients with ankylosing spondylitis.
Office visits for...
SAN FRANCISCO – Phase III clinical trial experience in using riociguat indicates that the drug is just as safe and effective in treating pulmonary arterial hypertension associated with connective...
SAN FRANCISCO – Triple therapy for rheumatoid arthritis using methotrexate, sulfasalazine, and hydroxychloroquine is less effective than the combination of tumor necrosis factor inhibitor and...
SAN FRANCISCO – Triple therapy for rheumatoid arthritis has shone in clinical trials, but its adoption by rheumatologists in the trenches of patient care has been lukewarm.
The challenges facing...
SAN FRANCISCO – Sarilumab, an investigational monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy at two different dose levels, compared with placebo, in patients with...
SAN FRANCISCO – Baricitinib, an investigational oral investigational JAK 1/2 inhibitor, was significantly superior to adalimumab and to placebo in the treatment of patients with active rheumatoid...
SAN FRANCISCO – Vectra DA, a multibiomarker blood test, can predict response to therapy for patients with rheumatoid arthritis, and it can also identify patients who can safely taper and...
SAN FRANCISCO – Mycophenolate significantly reduces the need for endoscopic interventions for gastric antral vascular ectasia in patients with systemic sclerosis, according to investigators...
